The activated seven lupus anticoagulant assay detects clinically significant antibodies.

about

Clinical usefulness of the dilute Russell viper venom time test for patients taking warfarin.

P2860

Q47399290-BBAAF91A-E46C-4641-9E3D-4701792A3DC7

P2860

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

Item

http://www.wikidata.org/entity/Q45871506

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@en

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@nl

type

Item

label

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@en

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@nl

prefLabel

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@en

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@nl

P1476

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

@en

P2093

Gary W Moore

http://www.w3.org/2001/XMLSchema#string

Geoffrey F Savidge

http://www.w3.org/2001/XMLSchema#string

Savita Rangarajan

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Clinical significance of lupus anticoagulants in children.

Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines.

Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease.

Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis.

Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces.

The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus.

beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

P304

332-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029607305099

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17895508

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

about

P2860

P2860

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921